Literature DB >> 1299076

Recent developments in diabetes epidemiology in Europe.

J H Fuller1.   

Abstract

Recent developments in diabetes epidemiology in Europe have included the completion of the European Community sponsored Concerted Action on the Epidemiology and Prevention of Diabetes (Eurodiab), further studies of diabetes and coronary heart disease prevalence in ethnic minority groups in the United Kingdom, and studies of the effect of poor fetal and early post-natal nutrition on the risk of developing non-insulin dependent diabetes (NIDDM). The EURODIAB Concerted Action Programme has provided valuable new information on the incidence of insulin-dependent diabetes mellitus (IDDM) throughout Europe and has drawn attention to an unexpectedly high incidence in Sardinia. In the EURODIAB IDDM complications study, the prevalence of both large- and small-vessel complications of diabetes has been examined, using standardized methods, in 3,279 IDDM patients from 31 centres throughout Europe. The data on risk factors for complications obtained from this study will have significant health policy implications for diabetes in Europe which will be utilized by the current St. Vincent Declaration Action Programme for Diabetes Care and Research in Europe. In another part of the EURODIAB Concerted Action Programme, important information has been obtained on the validity of routinely-collected diabetes health information, such as mortality statistics based on death certificates, and estimates of diabetes prevalence obtained from drug-utilization data.

Entities:  

Mesh:

Year:  1992        PMID: 1299076

Source DB:  PubMed          Journal:  World Health Stat Q        ISSN: 0379-8070


  2 in total

1.  Does it matter where I live in Western Europe? An analysis of regional mortality differentials in Belgium, Germany and the Netherlands.

Authors:  W J Van Der Veen
Journal:  Eur J Popul       Date:  1994

Review 2.  Diabetes mellitus and the St Vincent Declaration. The economic implications.

Authors:  B Leese
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.